A fixed-dose combination (FDC) ophthalmic solution containing a non-selective beta-adrenergic receptor blocker (Timolol) and a selective alpha-2 adrenergic receptor agonist (Brimonidine). This combination is primarily used for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. The dual mechanism provides additive IOP-lowering efficacy, often with a more favorable side effect profile compared to higher doses of a single agent, and may improve patient adherence.
Adult: One drop in the affected eye(s) twice daily (approximately every 12 hours). Do not exceed two times daily administration.
Note: Wash hands before use. Tilt head back, pull lower eyelid down to form a pouch. Instill one drop. Close eyes gently and apply pressure to the nasolacrimal duct (inner corner of eye) for 1-2 minutes to minimize systemic absorption. Wait at least 5 minutes before instilling any other topical ophthalmic medication. Do not touch dropper tip to eye or any surface.
The combination works via two distinct pathways to reduce aqueous humor production and may slightly increase uveoscleral outflow. Timolol blocks beta-1 and beta-2 adrenergic receptors in the ciliary body, reducing the formation of aqueous humor. Brimonidine stimulates alpha-2 adrenoceptors, primarily decreasing aqueous humor production and secondarily increasing uveoscleral outflow. Their effects are additive.
Pregnancy: Category C (US FDA). Timolol: Animal studies show fetotoxicity. Brimonidine: No adequate studies. Use only if potential benefit justifies potential fetal risk. Can cause fetal bradycardia. Avoid especially in first trimester.
Driving: May cause transient blurred vision, dizziness, and fatigue. Patients should not drive or use machines until their vision is clear and they know how the medication affects them.
| Oral Beta-Blockers (e.g., Propranolol, Metoprolol) | Additive systemic beta-blockade; increased risk of bradycardia, AV block, heart failure. | Major |
| Calcium Channel Blockers (e.g., Verapamil, Diltiazem) | Potentiates negative inotropic and chronotropic effects; risk of severe bradycardia and heart failure. | Major |
| Digoxin | Additive effects on AV conduction; increased risk of bradycardia. | Moderate |
| Clonidine (systemic) | Additive alpha-2 agonist effects; potential for rebound hypertension if clonidine is withdrawn. | Moderate |
| MAO Inhibitors (e.g., Phenelzine, Tranylcypromine) | May potentiate the systemic vasopressor effects of brimonidine; avoid concomitant use. | Major |
| Antihypertensives (ACE inhibitors, Diuretics) | Additive hypotensive effect. | Moderate |
| Insulin, Oral Hypoglycemics | Timolol may mask tachycardia as a sign of hypoglycemia and may impair glucose recovery. | Moderate |
| CNS Depressants (Alcohol, Benzodiazepines, Opioids) | May potentiate the sedative effects of brimonidine. | Moderate |
Same composition (Timolol (5mg) + Brimonidine (1.5mg)), different brands: